Abcellera Biologics Inc (ABCL)

$3.54 +0.10 (2.91%)
Market Cap 1.04B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 2,409,600
Avg Vol 3,439,062
Day's Range N/A - N/A
Shares Out 303.16M
Stochastic %K 71%
Beta 0.85
Analysts Strong Sell
Price Target $9.17

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
DragonAlgo
DragonAlgo Apr. 11 at 9:06 PM
🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $12.00 | Type: CALL Option Plan (premium): Entry: $0.04 Stop: $0.03 TP1: $0.05 TP2: $0.07 TP3: $0.10 🔗 https://dragonalgo.com
0 · Reply
tradersunion353
tradersunion353 Apr. 11 at 5:40 PM
$ABCL Real talk: down 90%+ from IPO. Five consecutive years of losses. If you’re still calling this bullish— you’re not a long, you’re married to the stock. There’s a difference. Save the “biotech is volatile” speech. Volatile goes both ways. Other biotechs went UP in this window. I hold this too. every long investors deserves returns.
1 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 11 at 2:46 PM
$ABCL $IBRX $PLTR Public Short to Float $IBRX - 39.34% https://finviz.com/quote.ashx?t=IBRX&ty=c&ta=1&p=d $ABCL - 21.69% https://finviz.com/quote.ashx?t=ABCL&ty=c&ta=1&p=d $PLTR - 2.31% (excludes options) https://finviz.com/quote.ashx?t=PLTR&ty=c&ta=1&p=d
1 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 11 at 2:33 PM
$ABCL
0 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 11 at 2:33 PM
$ABCL $IBRX $PLTR etc Disrupt the short sellers by making your holdings unavailable for borrowing by closing your margin accounts. (Which aren’t a real good idea for retail investors anyway.)
1 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 11 at 1:00 PM
$ABCL
0 · Reply
StockMacroView
StockMacroView Apr. 11 at 7:50 AM
I favor $ABCL and CEO Carl Hansen for their disciplined capital strategy. While not void of capital increases, they haven't crushed shareholders with post-IPO dilution. Major fundraising was confined to the IPO era; since then, despite filing a shelf registration, there's no evidence of large-scale offerings. This restraint in dilution is a significant green flag for the stock. 👉Click to view @StockMacroView for timely updates amid the volatility.
1 · Reply
MoneyClaw
MoneyClaw Apr. 10 at 9:29 PM
$ABCL cheers to A good looking next week
0 · Reply
Art_BunyaaHa
Art_BunyaaHa Apr. 10 at 8:11 PM
$ABCL
0 · Reply
MoneyClaw
MoneyClaw Apr. 10 at 7:23 PM
$ABCL looking good!
0 · Reply
Latest News on ABCL
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Apr 1, 2026, 4:05 PM EDT - 10 days ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 6 weeks ago

AbCellera Reports Full Year 2025 Business Results

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Feb 11, 2026, 4:05 PM EST - 2 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 22, 2026, 4:05 PM EST - 2 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Jan 12, 2026, 9:00 AM EST - 3 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 18, 2025, 9:00 AM EST - 4 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 4:05 PM EST - 4 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 5 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 5 months ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 7 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 8 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 8 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 11 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 11 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 11 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 19, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

Mar 11, 2024, 9:00 AM EDT - 2 years ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Mar 5, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

AbCellera Announces Resignation of Board Member

Feb 23, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Resignation of Board Member

AbCellera to Present at Upcoming Investor Conferences in March

Feb 22, 2024, 8:15 PM EST - 2 years ago

AbCellera to Present at Upcoming Investor Conferences in March

DragonAlgo
DragonAlgo Apr. 11 at 9:06 PM
🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $12.00 | Type: CALL Option Plan (premium): Entry: $0.04 Stop: $0.03 TP1: $0.05 TP2: $0.07 TP3: $0.10 🔗 https://dragonalgo.com
0 · Reply
tradersunion353
tradersunion353 Apr. 11 at 5:40 PM
$ABCL Real talk: down 90%+ from IPO. Five consecutive years of losses. If you’re still calling this bullish— you’re not a long, you’re married to the stock. There’s a difference. Save the “biotech is volatile” speech. Volatile goes both ways. Other biotechs went UP in this window. I hold this too. every long investors deserves returns.
1 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 11 at 2:46 PM
$ABCL $IBRX $PLTR Public Short to Float $IBRX - 39.34% https://finviz.com/quote.ashx?t=IBRX&ty=c&ta=1&p=d $ABCL - 21.69% https://finviz.com/quote.ashx?t=ABCL&ty=c&ta=1&p=d $PLTR - 2.31% (excludes options) https://finviz.com/quote.ashx?t=PLTR&ty=c&ta=1&p=d
1 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 11 at 2:33 PM
$ABCL
0 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 11 at 2:33 PM
$ABCL $IBRX $PLTR etc Disrupt the short sellers by making your holdings unavailable for borrowing by closing your margin accounts. (Which aren’t a real good idea for retail investors anyway.)
1 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 11 at 1:00 PM
$ABCL
0 · Reply
StockMacroView
StockMacroView Apr. 11 at 7:50 AM
I favor $ABCL and CEO Carl Hansen for their disciplined capital strategy. While not void of capital increases, they haven't crushed shareholders with post-IPO dilution. Major fundraising was confined to the IPO era; since then, despite filing a shelf registration, there's no evidence of large-scale offerings. This restraint in dilution is a significant green flag for the stock. 👉Click to view @StockMacroView for timely updates amid the volatility.
1 · Reply
MoneyClaw
MoneyClaw Apr. 10 at 9:29 PM
$ABCL cheers to A good looking next week
0 · Reply
Art_BunyaaHa
Art_BunyaaHa Apr. 10 at 8:11 PM
$ABCL
0 · Reply
MoneyClaw
MoneyClaw Apr. 10 at 7:23 PM
$ABCL looking good!
0 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 10 at 7:04 PM
$ABCL
0 · Reply
Stocktradesmoon
Stocktradesmoon Apr. 10 at 6:43 PM
$ABCL $ABCL Let the haters hate. Let the non-believers not believe. You don’t get rich following the herd. You make it by getting in early and buying when nobody else wanted it. They will become believers soon enough. Not much green out there today. Well some 🙏🦾🤔
0 · Reply
Danz_Trades
Danz_Trades Apr. 10 at 6:33 PM
$ABCL long Should double from here soon
1 · Reply
DragonAlgo
DragonAlgo Apr. 10 at 4:52 PM
🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $12.00 | Type: CALL Option Plan (premium): Entry: $0.04 Stop: $0.03 TP1: $0.05 TP2: $0.07 TP3: $0.10 Momentum tape remains active. 🔗 https://dragonalgo.com
0 · Reply
MoneyClaw
MoneyClaw Apr. 10 at 3:24 PM
$ABCL if it holds 3.50 i can see a steady climb.
0 · Reply
DeMampCamp
DeMampCamp Apr. 10 at 2:18 PM
$ABCL How about you take some accountability here, you and majority of others, myself included, just simply bought far too soon!
1 · Reply
UncleTomFlorida
UncleTomFlorida Apr. 10 at 1:11 PM
$ABCL # Funds Holding AbCellera Q2 2024 - 8 Q3 2024 - 9 Q4 2024 - 7 Q1 2025 - 7 Q2 2025 - 8 Q3 2025 - 8 Q4 2025 - 10 source: probabli.xyz/ 13F Filings Bullish
0 · Reply
DragonAlgo
DragonAlgo Apr. 10 at 12:40 AM
🐉 $ABCL CALL — DragonAlgo® Signal Contract: ABCL CALL Expiry: 2026-04-17 | Strike: $12.00 | Type: CALL Option Plan (premium): Entry: $0.04 Stop: $0.03 TP1: $0.05 TP2: $0.07 TP3: $0.10 🔗 https://dragonalgo.com
0 · Reply
bonecrack_benny
bonecrack_benny Apr. 9 at 11:16 PM
$ABCL
1 · Reply
tradersunion353
tradersunion353 Apr. 9 at 10:11 PM
$ABCL Can we have $10 to $12 so some of the longs here who are not married to stock can book profits and move? we have been waiting for 3 plus years. so far you have been #1 Overhyped and under performed stock
0 · Reply
DeMampCamp
DeMampCamp Apr. 9 at 8:41 PM
$ABCL Ignore the noise! We finished green and one day closer to our Q3 read out, stay the course peeps!
1 · Reply
tradersunion353
tradersunion353 Apr. 9 at 7:47 PM
$ABCL Market is sharply up this week. Meanwhile this POS is struggling to stay green Yes those are satisfied just adding and looking for profits can keep adding forever.
1 · Reply